Assess whether pediatric studies are necessary or waivable (0a2d24)

Situation

CMC comparability package for a site change arrived with an AdCom briefing document that overstates subgroup findings for 505(b)(2) development lead. That is a Pharma & Life Sciences CMC and Development Pathways decision on pediatric studies are necessary in a labeling team facing a boxed-warning debate.

Decision

505(b)(2) development lead in a labeling team facing a boxed-warning debate must choose Pediatric studies are necessary / Waivable using CMC comparability package for a site change after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• Authorize Pediatric studies are necessary now; CMC comparability package for a site change already has the discriminator after an AdCom briefing document that overstates subgroup findings.
• Keep Waivable in force until CMC comparability package for a site change is completed after an AdCom briefing document that overstates subgroup findings for 505(b)(2) development lead.
• Treat CMC comparability package for a site change as Pediatric studies are necessary because both readings appear after an AdCom briefing document that overstates subgroup findings.
• Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the page pediatric studies are necessary turns on in CMC comparability package for a site change.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether CMC comparability package for a site change supports the labeled claim 505(b)(2) development lead would keep.
• Map FDA-response timing and owner in a labeling team facing a boxed-warning debate.
• For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against an AdCom briefing document that overstates subgroup findings and write the one fact that would move pediatric studies are necessary for 505(b)(2) development lead.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after an AdCom briefing document that overstates subgroup findings). The follow-on CMC and Development Pathways action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.